• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

By: Bragar Eagel & Squire via GlobeNewswire
October 07, 2025 at 18:05 PM EDT

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options

If you are a long-term stockholder in Alto between February 2, 2024 and October 22, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) --

What’s Happening:

  • Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Alto Neuroscience, Inc. (NYSE: ANRO) on behalf of long-term stockholders following a class action complaint that was filed against Alto on July 21, 2025 with a Class Period from February 2, 2024 to October 22, 2024. Our investigation concerns whether the board of directors of Alto have breached their fiduciary duties to the company.

Details:

  • According to the complaint, the Offering Documents in support of the IPO were negligently prepared. Additionally, during the class period, defendants failed to disclose that: (i) ALTO-100 was less effective in treating MDD than defendants had led investors to believe; (ii) accordingly, ALTO-100’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Alto’s business and/or financial prospects were overstated.
  • On October 22, 2024, Alto issued a press release announcing topline results from the Phase 2b trial evaluating ALTO-100 as a treatment for MDD. That press release stated, in relevant part, that “ALTO-100 in patients with [MDD] did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.” On this news, Alto’s stock price fell $10.17 per share, or 69.99%, to close at $4.36 per share on October 23, 2024.

Next Steps:

  • If you are a long-term stockholder of Alto, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com


Primary Logo

More News

View More
MarketBeat Week in Review – 10/27 - 10/31
Today 7:00 EDT
Via MarketBeat
Tickers AMZN AVGO CARR FUN GOOGL INTC
Amazon Earnings: 3 Catalysts That Could Drive Shares to $300
October 31, 2025
Via MarketBeat
Tickers AMZN GOOG GOOGL
Why Chipotle Stock May Bounce After a Brutal Sell-Off
October 31, 2025
Via MarketBeat
Tickers CMG
Why VGT May Be a Smarter Bet Than Chasing Individual Tech Stocks
October 31, 2025
Via MarketBeat
Tickers AAPL AVGO MSFT NVDA VGT
Equinix Stock Rises Despite Lower Revenue Guidance
October 31, 2025
Via MarketBeat
Tickers EQIX META MSFT

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.22
+21.36 (9.58%)
AAPL  270.37
-1.03 (-0.38%)
AMD  256.12
+1.28 (0.50%)
BAC  53.45
+0.42 (0.79%)
GOOG  281.82
-0.08 (-0.03%)
META  648.35
-18.12 (-2.72%)
MSFT  517.81
-7.95 (-1.51%)
NVDA  202.49
-0.40 (-0.20%)
ORCL  262.61
+5.72 (2.23%)
TSLA  456.56
+16.46 (3.74%)
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap